Topics covered: Reimbursement Trends, Orphan Drugs, Orphan Drug and Biologics Manufacturing, Oncology Drug Development, Health Care, FDA Approval Process, Biotechnology and Pharmaceuticals, Biotechnology and Pharmaceutical Investing
Companies covered: Neostem, Inc. (NASDAQ:NBS), Provectus Biopharmaceuticals, Inc. (AMEX:PVCT), Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB), Array BioPharma Inc. (NASDAQ:ARRY), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen Inc. (NASDAQ:AMGN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), VIVUS, Inc. (NASDAQ:VVUS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Novartis AG (NYSE:NVS), GlaxoSmithKline PLC (NYSE:GSK), Gilead Sciences, Inc. (NASDAQ:GILD), Cubist Pharmaceuticals Inc., AstraZeneca PLC (NASDAQ:AZN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Onyx Pharmaceuticals Inc., NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Coca-Cola Company (The) (NYSE:KO), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), Immunomedics, Inc. (NASDAQ:IMMU), International Business Machines Corporation (NYSE:IBM), Sanofi (NYSE:SNY), Pfizer, Inc. (NYSE:PFE), Novo Nordisk A/S (NYSE:NVO), Merck & Company, Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), Abbott Laboratories (NYSE:ABT)
